Sirolimus vs paclitaxel-coated balloons in in-stent coronary restenosis: A meta-analysis

Table 1 Study characteristics and patient baseline demographics

Ref.	Study design	Country	Follow up period	Sample size		Age, year; mean ± SD		Male (%)		Diabetes mellitus (%)		Hypertension (%)		Hyperlipidemia (%)		Smoking (%)
				SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB
Ali et al[7], 2019	RCT	United States	6 months	25	25	61.6 ± 11.7	58.6 ± 21.5	88	76	72	76	96	92	92	84	16	8
Liu et al[20], 2025	RCT	China	12 months	130	128	63.8 ± 9.3	63.7 ± 8.5	73.1	75.8	33.8	41.4	66.9	70.3	17.7	14.1	NA	NA
Ray et al[19], 2025	Prospective observational study	India	41 months	53	32	67.19 ± 8.21	63.50 ± 8.54	86.8	96.9	73.6	81.3	71.7	84.4	N/A	N/A	N/A	N/A
Scheller et al[8], 2022	RCT	Malaysia, German, Switzerland	12 months	50	51	67 ± 12	63 ± 12	86	76	54	59	98	94	88	84	22	12

SCB: Sirolimus coated balloon; PCB: Paclitaxel coated balloon; N/A: Not applicable.

Table 2 Procedural characteristics of interventions for in-stent restenosis

Ref.	DCB length mm		DCB diameter, mm		Dissection (%)		Balloon pressure (bar)		Balloon inflation time (s)		Minimal lumen diameter pre-PCI in-lesion (mm)		Minimal lumen diameter pre-PCI in-segment (mm)
	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB
Ali et al[7], 2019	N/A	N/A	2.91 ± 0.39	2.93 ± 0.37	4	0%	11.6 ± 3.2 (26)	10.3 ± 2.8 (25)	59.0 ± 7.1 (26)	59.3 ± 6.1 (25)	0.81 ± 0.34	0.80 ± 0.52	0.81 ± 0.35	0.80 ± 0.52
Liu et al[20], 2025	23.0 ± 6.2	22.6 ± 6.2	3.0 ± 0.4	3.0 ± 0.4	0	0%	9.3 ± 2.7 (149)	9.4 ± 2.8 (141)	58.8 ± 12.5 (149)	57.2 ± 13.4 (141)	0.86 ± 0.41	0.94 ± 0.36	N/A	N/A
Ray et al[19], 2025	29.58 ± 7.98	24.11 ± 6.54	3.31 ± 0.39	3.20 ± 0.43	N/A	N/A	N/A	N/A	60	60	N/A	N/A	N/A	N/A
Scheller et al[8], 2022	N/A	N/A	3.03 ± 0.40	2.98 ± 0.56	2	0%	11 ± 3	9 ± 3	58 ± 13	54 ± 12	0.85 ± 0.49	0.83 ± 0.49	0.82 ± 0.40	0.80 ± 0.44

SCB: Sirolimus coated balloon; PCB: Paclitaxel coated balloon; N/A: Not applicable.